Joseph Friedman1, Fernando Montero2, Phillippe Bourgois3, Rafik Wahbi4, Daniel Dye5, David Goodman-Meza6, Chelsea Shover7. 1. Center for Social Medicine and Humanities, University of California, Los Angeles, CA, USA; Medical Informatics Home Area, University of California, Los Angeles, CA, USA. Electronic address: joseph.robert.friedman@gmail.com. 2. Department of Anthropology, Columbia University, New York, NY, USA. 3. Center for Social Medicine and Humanities, University of California, Los Angeles, CA, USA. Electronic address: pbourgois@gmail.com. 4. Fielding School of Public Health, University of California, Los Angeles, CA, USA. 5. Department of Pathology, University of Alabama, Birmingham, AL, USA. 6. Division of Infectious Diseases, University of California, Los Angeles, CA, USA. 7. Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, CA, USA. Electronic address: CLShover@mednet.ucla.edu.
Abstract
BACKGROUND: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. METHODS: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs. RESULTS: In 10 jurisdictions - representing all four US Census Regions - xylazine was increasingly present in overdose deaths, rising from 0.36% of deaths in 015m 6.7% in 2020. The highest xylazine prevalence data was observed in Philadelphia, (25.8% of deaths), followed by Maryland (19.3%) and Connecticut (10.2%). Illicitly-manufactured-fentanyls were present in 98.4% of xylazine-present-overdose-deaths - suggesting a strong ecological link - as well as cocaine (45.4%), benzodiazepines (28.4%), heroin (23.3%), and alcohol (19.7%). PWID in Philadelphia described xylazine as a sought-after adulterant that lengthens the short duration of fentanyl injections. They also linked it to increased risk of soft tissue infection and naloxone-resistant overdose. CONCLUSIONS: Xylazine is increasingly present in overdose deaths, linked to the proliferation of illicitly-manufactured-fentanyls. Ethnographic accounts associate it with profound risks for PWID. Nevertheless, many jurisdictions do not routinely test for xylazine, and it is not comprehensively tracked nationally. Further efforts are needed to provide PWID with services that can help minimize additional risks associated with a shifting drug supply.
BACKGROUND: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. METHODS: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs. RESULTS: In 10 jurisdictions - representing all four US Census Regions - xylazine was increasingly present in overdose deaths, rising from 0.36% of deaths in 015m 6.7% in 2020. The highest xylazine prevalence data was observed in Philadelphia, (25.8% of deaths), followed by Maryland (19.3%) and Connecticut (10.2%). Illicitly-manufactured-fentanyls were present in 98.4% of xylazine-present-overdose-deaths - suggesting a strong ecological link - as well as cocaine (45.4%), benzodiazepines (28.4%), heroin (23.3%), and alcohol (19.7%). PWID in Philadelphia described xylazine as a sought-after adulterant that lengthens the short duration of fentanyl injections. They also linked it to increased risk of soft tissue infection and naloxone-resistant overdose. CONCLUSIONS: Xylazine is increasingly present in overdose deaths, linked to the proliferation of illicitly-manufactured-fentanyls. Ethnographic accounts associate it with profound risks for PWID. Nevertheless, many jurisdictions do not routinely test for xylazine, and it is not comprehensively tracked nationally. Further efforts are needed to provide PWID with services that can help minimize additional risks associated with a shifting drug supply.
Authors: Clara Fleiz; Jaime Arredondo; Alfonso Chavez; Lilia Pacheco; Luis A Segovia; Jorge A Villatoro; Silvia L Cruz; María E Medina-Mora; Juan R de la Fuente Journal: Addiction Date: 2020-01-28 Impact factor: 6.526
Authors: Anneli Uusküla; Ave Talu; Sigrid Vorobjov; Maris Salekešin; Jürgen Rannap; Liis Lemsalu; Don Des Jarlais Journal: Int J Drug Policy Date: 2020-05-13
Authors: Chelsea L Shover; Titilola O Falasinnu; Candice L Dwyer; Nayelie Benitez Santos; Nicole J Cunningham; Rohan B Freedman; Noel A Vest; Keith Humphreys Journal: Drug Alcohol Depend Date: 2020-09-28 Impact factor: 4.492
Authors: Kathleen M Ward; Ayden Scheim; Jonathan Wang; Benjamin Cocchiaro; Katie Singley; Alexis M Roth Journal: Drug Alcohol Depend Rep Date: 2022-04-26
Authors: Madeline C Frost; Elizabeth J Austin; Maria A Corcorran; Elsa S Briggs; Czarina N Behrends; Alexa M Juarez; Noah D Frank; Elise Healy; Stephanie M Prohaska; Paul A LaKosky; Shashi N Kapadia; David C Perlman; Bruce R Schackman; Don C Des Jarlais; Emily C Williams; Sara N Glick Journal: Harm Reduct J Date: 2022-07-19